Clinical Trial

Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined with Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal Junction Adenocarcinoma.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-15
Trial Details
NCT Number NCT07643623
Lead Sponsor Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Conditions Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Enrollment 720 participants
Start Date 2026-07-31
Primary Completion 2031-12-31 (estimated)
Study Completion 2031-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-14